Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo

Cancer Discovery

Volumn 3, Issue 6, 2013, Pages 616-629

  Kocher, Brandon ^a   Piwnica Worms, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; KALLIKREIN; LUCIFERASE; PROBASIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; VASCULOTROPIN RECEPTOR 3;

ARTICLE; BIOLUMINESCENCE; GENE TARGETING; GENETIC TRANSFORMATION; IMMUNOGENICITY; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSGENIC ORGANISM; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WHOLE BODY IMAGING;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; NEOPLASMS;

EID: 84878856575     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0503     Document Type: Article

References (102)

1. Bissell M, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21: 309-22.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
5. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147:992-1009.
6. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001;98: 12072-7.
7. Pazolli E, Stewart SA. Senescence: the good the bad and the dysfunctional. Curr Opin Genet Dev 2008;18:42-7.
8. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009;15:6630-8.
9. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
10. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
11. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351-4.
12. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1: 508-23.
13. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-87.
14. Sharpless N, Depinho R. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
15. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010;10:470-80.
16. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol 2011;6:95-119.
17. Villalobos V, Naik S, Piwnica-Worms D. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng 2007;9:321-49.
18. Singer R, Lawrence D, Ovryn B, Condeelis J. Imaging of gene expression in living cells and tissues. J Biomed Opt 2005;10:051406.
19. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
20. Dothager R, Flentie K, Moss B, Pan M, Kesarwala A, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 2009;20:45-53.
21. Condeelis J, Weissleder R. In vivo imaging in cancer. Cold Spring Harb Perspect Biol 2010;2:a003848.
22. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005;7:5-15.
23. Giepmans BN, Adams SR, Ellisman MH, Tsien RY. The fluorescent toolbox for assessing protein location and function. Science 2006;312:217-24.
24. Bhang HE, Pomper MG. Cancer imaging: gene transcription-based imaging and therapeutic systems. Int J Biochem Cell Biol 2012;44:684-9.
25. Tobias A, Ahmed A, Moon K, Lesniak M. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 2013;84:213-22.
26. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002;4:235-60.
27. Cheng T, Roffler S, Tzou S, Chuang K, Su Y, Chuang C, et al. An activity-based near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues. J Am Chem Soc 2012;134:3103-10.
28. Luker G, Sharma V, Pica C, Dahlheimer J, Li W, Ochesky J, et al. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 2002;99:6961-6.
29. Tjuvajev J, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996;56:4087-95.
30. Blasberg R, Piwnica-Worms D. Imaging: strategies, controversies, and opportunities. Clin Cancer Res 2012;18:631-7.
31. Louie A, Huber M, Ahrens E, Rothbacher U, Moats R, Jacobs R, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321-5.
32. Wack S, Hajri A, Heisel F, Sowinska M, Berger C, Whelan M, et al. Feasibility, sensitivity, and reliability of laser-induced fluorescence imaging of green fluorescent protein-expressing tumors in vivo. Mol Ther 2003;7:765-73.
33. Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 1999;12:1035-40.
34. Thompson JF, Hayes LS, Lloyd DB. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 1991; 103:171-7.
35. Zhao H, Doyle T, Wong R, Cao Y, Stevenson D, Piwnica-Worms D, et al. Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol Imaging 2004;3:43-54.
36. Pichler A, Prior J, Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A 2004;101:1702-7.
37. Tinkum KL, Marpegan L, White LS, Sun J, Herzog ED, Piwnica-Worms D, et al. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol Cell Biol 2011;31:3759-72.
38. Ilagan MX, Lim S, Fulbright M, Piwnica-Worms D, Kopan R. Real-time imaging of notch activation with a luciferase complementation-based reporter. Sci Signal 2011;4:rs7.
39. Spiller DG, Wood CD, Rand DA, White MR. Measurement of single-cell dynamics. Nature 2010;465:736-45.
40. Higgins LJ, Pomper MG. The evolution of imaging in cancer: current state and future challenges. Semin Oncol 2011;38:3-15.
41. Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 2006;66:10513-6.
42. Lyons SK, Lim E, Clermont AO, Dusich J, Zhu L, Campbell KD, etal. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res 2006;66:4701-7.
43. Seethammagari MR, Xie X, Greenberg NM, Spencer DM. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006;66:6199-209.
44. Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, etal. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 2007;67:685-91.
45. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
46. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
47. Gross S, Abraham U, Prior JL, Herzog ED, Piwnica-Worms D. Continuous delivery of d-luciferin by implanted micro-osmotic pumps enables true real-time bioluminescence imaging of luciferase activity in vivo. Mol Imaging 2007;6:121-30.
48. Ohtani N, Imamura Y, Yamakoshi K, Hirota F, Nakayama R, Kubo Y, et al. Visualizing the dynamics of p21(Waf1/Cip1) cyclin-dependent kinase inhibitor expression in living animals. Proc Natl Acad Sci USA 2007;104:15034-9.
49. Vasey DB, Wolf CR, MacArtney T, Brown K, Whitelaw CB. p21-LacZ reporter mice reflect p53-dependent toxic insult. Toxicol Appl Pharmacol 2008;227:440-50.
50. Scotto L, Kruithof-de Julio M, Paoluzzi L, Kalac M, Marchi E, Buitrago JB, et al. Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. Clin Cancer Res 2012;18:3803-11.
51. Martinez-Corral I, Olmeda D, Dieguez-Hurtado R, Tammela T, Alitalo K, Ortega S. In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. Proc Natl Acad Sci U S A 2012;109:6223-8.
52. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, etal. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454:656-60.
53. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008;7:2272-9.
54. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008;68:4754-62.
55. Spiotto MT, Banh A, Papandreou I, Cao H, Galvez MG, Gurtner GC, et al. Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res 2010;70:78-88.
56. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007;67:10631-4.
57. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002;415:92-6.
58. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001;107:881-91.
59. Iwawaki T, Akai R, Kohno K, Miura M. A transgenic mouse model for monitoring endoplasmic reticulum stress. Nat Med 2004;10: 98-102.
60. Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, Reiss M, et al. Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS ONE 2011;6:e18269.
61. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW, et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 2006;103:105-10.
62. Kadonosono T, Kuchimaru T, Yamada S, Takahashi Y, Murakami A, Tani T, et al. Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imaging. PLoS ONE 2011;6:e26640.
63. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008;15:621-7.
64. Pichler A, Prior JL, Luker GD, Piwnica-Worms D. Generation of a highly inducible Gal4->Fluc universal reporter mouse for in vivo bioluminescence imaging. Proc Natl Acad Sci U S A 2008;105:15932-7.
65. Pan MH, Lin J, Prior JL, Piwnica-Worms D. Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice. Mol Cancer Ther 2010;9: 2752-60.
66. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
67. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004;10:1257-60.
68. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003; 63:7042-6.
69. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti P, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525-33.
70. Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol 2011;179:502-12.
71. Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 2011;121:800-8.
72. Mehasseb MK, Bell SC, Habiba MA. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction 2009;138: 341-50.
73. Higashi AY, Ikawa T, Muramatsu M, Economides AN, Niwa A, Okuda T, et al. Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. J Immunol 2009;182:5633-40.
74. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, et al. Doxycycline-mediated quantitative and tissue-specifi c control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 1996;93:10933-8.
75. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 1994;91:9302-6.
76. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-51.
77. Du YC, Klimstra DS, Varmus H. Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS ONE 2009;4:e6932.
78. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev 2010;24:1059-72.
79. Hunter KW. Mouse models of cancer: does the strain matter? Nat Rev Cancer 2012;12:144-9.
80. Ishikawa TO, Jain NK, Taketo MM, Herschman HR. Imaging cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase knock-in reporter gene. Mol Imaging Biol 2006;8:171-87.
81. Dussmann P, Pagel JI, Vogel S, Magnusson T, Zimmermann R, Wagner E, et al. Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing. BMC Dev Biol 2011;11:28.
82. Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci U S A 2009;106:5394-9.
83. Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, et al. Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers. Am J Pathol 2010;176:1629-38.
84. Jia W, Wang S, Horner JW, Wang N, Wang H, Gunther EJ, et al. A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J 2011;25:979-89.
85. Wang Y, Iyer M, Annala A, Wu L, Carey M, Gambhir S. Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice. Physiol Genomics 2006;24:173-80.
86. Faley SL, Takahashi K, Crooke CE, Beckham JT, Tomemori T, Shappell SB, et al. Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis. Mol Imaging 2007;6:331-9.
87. Zhang N, Fang Z, Contag PR, Purchio AF, West DB. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004;103:617-26.
88. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. J Immunol 2002;168:1441-6.
89. Lin AH, Luo J, Mondshein LH, ten Dijke P, Vivien D, Contag CH, et al. Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury. J Immunol 2005;175:547-54.
90. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway dependent tumors in mice. Cancer Res 2002;62:1862-7.
91. Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 2008;68: 2241-9.
92. Pihlajamaa P, Zhang FP, Saarinen L, Mikkonen L, Hautaniemi S, Janne OA. The phytoestrogen genistein is a tissue-specific androgen receptor modulator. Endocrinology 2011;152:4395-405.
93. Lu X, Guo H, Molter J, Miao H, Gerber L, Hu Y, et al. Alpha-fetoprotein-thymidine kinase-luciferase knockin mice: a novel model for dual modality longitudinal imaging of tumorigenesis in liver. J Hepatol 2011;55:96-102.
94. Park JH, Kim KI, Lee YJ, Lee TS, Kim KM, Nahm SS, et al. Non-invasive monitoring of hepatocellular carcinoma in transgenic mouse with bioluminescent imaging. Cancer Lett2 011;310:53-60.
95. Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS ONE 2011;6:e18727.
96. Zumsteg A, Strittmatter K, Klewe-Nebenius D, Antoniadis H, Christofori G. A bioluminescent mouse model of pancreatic {beta}-cell carcinogenesis. Carcinogenesis 2010;31:1465-74.
97. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker M, etal. In vivo imaging of transcriptionally active estrogen receptors. Nat Med 2003;9:82-6.
98. Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, KaelinWG. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2003;2:297-302.
99. Buschow C, Charo J, Anders K, Loddenkemper C, Jukica A, Alsamah W, et al. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J Immunol 2010;184:2930-8.
100. Liu J, Esmailpour T, Shang X, Gulsen G, Liu A, Huang T. TBX3 over-expression causes mammary gland hyperplasia and increases mammary stem-like cells in an inducible transgenic mouse model. BMC Dev Biol 2011;11:65.
101. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003;17:488-501.
102. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of highgrade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res 2009;69:4407-14.